May 9 |
Editas Medicine upgraded at J.P. Morgan on recent weakness
|
May 9 |
Editas Medicine First Quarter 2024 Earnings: Misses Expectations
|
May 9 |
Q1 2024 Editas Medicine Inc Earnings Call
|
May 8 |
Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call Transcript
|
May 8 |
Editas Medicine down 9% following rough Q1 results
|
May 8 |
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
|
May 8 |
Editas Medicine GAAP EPS of -$0.76 misses by $0.18, revenue of $1.14M misses by $6.16M
|
May 8 |
Editas Medicine Announces First Quarter 2024 Results and Business Updates
|
May 7 |
Editas Medicine Q1 2024 Earnings Preview
|
May 5 |
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 71%
|